Information Disclosure Statement of the Obligor
I. The Information Disclosure Obligor has prepared this report in accordance with the "Company Law of the People's Republic of China," "Securities Law of the People's Republic of China," "Administrative Measures for the Acquisition of Listed Companies," and "Format Rules for Information Disclosure of Publicly Issued Securities No. 15 – Report on Changes in Equity," and other relevant laws, regulations, and normative documents.
II. The Information Disclosure Obligor has obtained the necessary authorization and approval to sign this report, and its performance does not violate any provisions of its articles of association or internal regulations, nor does it conflict with them.
III. In accordance with the provisions of the aforementioned laws and regulations, this report fully discloses the changes in the equity interests held by the Information Disclosure Obligor in Chongqing Reme Pharmaceutical Co., Ltd.
IV. As of the date of signing this report, apart from the information disclosed herein, the Information Disclosure Obligor has not increased or decreased its voting rights in Chongqing Reme Pharmaceutical Co., Ltd. by any other means.
V. This equity change is based on the information contained in this report. Other than the Information Disclosure Obligor, no other person has been entrusted or authorized to provide information not listed in this report or to make any explanations or clarifications regarding this report.
VI. The Information Disclosure Obligor hereby undertakes that this report contains no false records, misleading statements, or significant omissions, and it assumes individual and joint legal liability for its truthfulness, accuracy, and completeness.